Progenity Slides Despite Being Granted Four Patents

By Sam Boughedda — Progenity Inc (NASDAQ:) stock fell 5.6% Wednesday, despite news the United States Patent and Trademark Office issued it four patents.

At the time of writing, Progenity shares are trading at $2.10.

The biotechnology firm said the patents relate to its ingestible technologies for the delivery of therapeutics through the gastrointestinal tract.

The first patent is named “Ingestible device for delivery of therapeutic agent to the gastrointestinal tract,” and is regarding techniques and devices for delivering a therapeutic agent into gastrointestinal tissue.

The second patent is to treat inflammatory conditions of the gastrointestinal tract with a Janus kinase (JAK) inhibitor. 

Additionally, it received a third patent entitled “Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor,” and a fourth under the title of “Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor.”

All four of the patents fall under Progenity’s GI-targeted therapeutics portfolio, which comprises more than 170 issued patents and continuing applications.

“We believe we hold one of the most robust ingestible device patent portfolios,” said Eric d’Esparbes, interim CEO of Progenity. 

“The addition of these recent patents further strengthens our intellectual property position and underscores our commitment to innovation in advancing therapeutic discovery, development, and delivery,” he added. 

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.